Résumé
La chirurgie anti-reflux est indiquée chez les porteurs d’un endobrachyœsophage uniquement après échec du traitement médical car le traitement chirurgical ne procure, ni une régression complète de l’épithélium métaplasique, ni une prévention du développement ultérieur de la dysplasie et/ou de l’adénocarcinome.
L’endobrachyœsophage avec sténose doit être traité par dilatations ou en cas d’échec, par chirurgie anti-reflux associée à une dilatation per-opératoire. Les sténoses résistantes aux dilatations justifient la résection avec reconstruction appropriée conçue en vue de prévenir le reflux acide.
Les ulcères de Barrett peuvent, dans la majorité des cas, être traités avec succès par les moyens médicaux. La chirurgie anti-reflux est efficace lorsque le traitement médical échoue. Les complications telles que les hémorragies massives ou la perforation, nécessitent indiscutablement un traitement chirurgical.
L’œsophago-gastrectomie est recommandée pour les patients dont les biopsies démontrent une dysplasie de haut degré et/ou un carcinome in situ, de même qu’en cas de cancer invasif.
Summary
Antireflux surgery for patients with Barrett’s esophagus is indicated only after failure of medical therapy since neither complete regression of the metaplastic epithelium nor prevention of the subsequent development of dysplasia and/or carcinoma is accomplished thereby.
Barrett’s esophagus with stricture may be managed by Gougienage, or, if this fails, by antireflux surgery coupled with intraoperative dilation. Strictures resistant to bougienage require resection with appropriate reconstruction designed to prevent acid reflux.
Barrett’s ulcers can be managed successfully by medical means in most cases. Antireflux surgery is successful when medical therapy fails. Complications such as massive hemorrhage or perforation, of course, require surgical intervention.
Esophagogastrectomy is recommended for patients with endoscopic biopsy evidence of high grade dysplasia/carcinoma in situ as it is for invasive carcinoma.
Références
ALTORKI N.K., SKINNER D.B., SEGALIN A.et al. — Indications for esophagectomy in non malignant Barrett’s esophagus: a 10 year experience.Ann. Thorac. Surg., 1990,49, 724–726.
ATTWOOD S.E.A., DEMEESTER T.R., BREMNER C.G.et al. — Alkaline gastroesophageal reflux in development of complications in Barrett’s columnar lined esophagus.Surgery, 1989,106, 764–770.
CAMERON A.J., ZINSMEISTER A.R., BALLARD D.J.et al. — Prevalence of columnar-lined (Barrett’s) esophagus.Gastroenterology, 1990,99, 918–922.
CAMERON A.J., OTT B.J., PAYNE W.S. — The incidence of adenocarcinoma in a columnar-lined (Barrett’s) esophagus.N. Eng. J. Med., 1985,313, 857–859.
DEMEESTER T.R., ATTWOOD S.E.A., SMYRK T.C.et al. — Surgical therapy in Barrett’s esophagus.Ann. Surg., 1990,212, 528–540.
ELLIS F.H. Jr., GIBB S.P. — Acid-suppression and alka-line-diversion: a safe and effective operation for patients with complex benign oesophageal diseare requiring reoperation. In Little A.G., Ferguson M.K., Skinner D.B. (eds). Diseases of esophagus. Vol. II Benign disease. Futura Publishing Co Mt. Kisko NY, 1990, pp. 391–400.
ELLIS F.H. Jr. — Treatment of carcinoma of the esophagus or cardia.Mayo Clin. Proc., 1989,64, 945–955.
GILEEN P., BYRNE P.J., HEALY M. — Implication of duodenogastric reflux in the pathogenesis of Barrett’s esophagus.Brit. J. Surg., 1988,75, 540–543.
HAMILTON S.R., HUTCHEON D.F., RAVICH W.J.et al. — Adenocarcinoma in Barrett’s esophagus after elimination of gastroesophageal reflux.Gastroenterology, 1984,86, 356–360.
IASCONE C., DEMEESTER T.R., LITTLE A.G., SKINNER D.B. — Barrett’s esophagus: functional assessment, proposed pathogenesis and surgical therapy.Arch. Surg., 1983,118, 543–549.
LACKEY C., RANKIN R.A., WALSH J.D. — Stricture location in Barrett’s esophagus.Gastrointest. Endosc., 1984,30, 331–333.
LEE F.I., ISAACS P.E. — Barrett’s ulcer: response to standard dose ranitidine, high dose ranitidine and omeprazole.Am. J. Gastroenterol., 1988,83, 914–916.
NAEF A.P., SAVARY M., OZZELLO L. — Columnar-lined lower esophagus: an acquired lesion with malignant predisposition.J. Thorac. Cardiovasc. Surg., 1975,70, 826–835.
OVASKAA J., MIETTINEN M., KIVILAAKSO E. — Adenocarcinoma arising in Barrett’s esophagus.Dig. Dis. Sci., 1989,34, 1336–1339.
PEARSON F.G., COOPER J.D., PATTERSON G.A., PRAKASH D. — Peptic ulcer in acquired columnar-lined esophagus: results of surgical treatment.Ann. Thorac. Surg., 1987,43, 241–244.
PERA M., TRASTEK V.F., CARPENTER H.A.et al. — Barrett’s esophagus with high-grade dysplasia: an indication for esophagectomy?Ann. Thorac. Surg., 1992,54, 193–198.
RIDDELL R.H. — Dysplasia and regression in Barrett’s epithelium. In: Spechler S.J., Goyal R. eds. Barrett’s esophagus, pathophysiology, diagnosis and management. New York, Elsevier, 1985, p. 49.
SAMPLINER R.E., GAREWELL H.S., FENNERTY M.S., AIKIEN M. — Lack of impact of therapy on extent of Barrett’s esophagus in 67 patients.Dig. Dis. Sci., 1990,35, 93–96.
SAVARY M., OLLYO J.B., MONNIER P. — Frequency and importance of endobrachyesophagus in reflux disease. In: Siewart J.R., Holscher A.H. (eds). Diseases of the esophagus. Springer-Verlag, Berlin, 1988, pp. 529–536.
SKINNER D.B., WALTHEN B.C., RIDDELL R.H.et al. — Barrett’s esophagus: comparison of benign and malignant cases.Ann. Surg., 1983,198, 554–565.
SKINNER D.B. — The incidence of cancer in Barrett’s esophagus varies according to series. In: Giuli R., McCallum R.W. eds. Benign lesions of the esophagus and cancer: answers to 210 questions. New York, NY, Springer-Verlag NY Inc, 1989, 764–765.
SPECHLER S.J., ROBBINS A.H., RUBINS H.E.et al. — Adenocarcinoma and Barrett’s esophagus: an overrated risk?Gastroenterology, 1984,87, 927–933.
STARNES V.A., ADKINS B., BALLINGER J.F., SAWYERS J.L. — Barrett’s esophagus. A surgical entity.Arch. Surg., 1984,119, 563–566.
STREITZ J.M., ANDREWS C.W. Jr., ELLIS F.H. Jr. — Surveillance endoscopy for Barrett’s esophagus. Does it help?J. Thorac. Cardiovasc. Surg., 1993,105, 383–387.
STREITZ J.M., ELLIS F.H. Jr, GIBB S.P.et al. — Adenocarcinoma in Barrett’s esophagus; a clinicopathologic study of 65 cases.Ann. Surg., 1991,213, 122–125.
WILLIAMSON W.A., ELLIS F.H. Jr., GIBB S.P.et al. — Effect of antireflux operation on Barrett’s mucosa.Ann. Thorac. Surg., 1990,49, 537–542.
WILLIAMSON W.A., ELLIS F.H. Jr., GIBB S.P., ARETZ H.T. — Barrett’s ulcer: a surgical disease?J. Thorac. Cardiovasc. Surg., 1992,103, 2–6.
WILLIAMSON W.A., ELLIS F.H. Jr., GIBB S.P.et al. — Barrett’s esophagus, prevalence and incidence of adenocarcinoma.Arch. Int. Med., 1991,151, 2212–2216.
WINTERS C. Jr., SPURLING T.S., CHOBANIAN S.J.et al. — Barett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease.Gastroenterology, 1987,92, 118–124.
Author information
Authors and Affiliations
About this article
Cite this article
Ellis, F.H. Indications du traitement chirurgical dans l’endobrachyœsophage. Acta Endosc 23, 101–108 (1993). https://doi.org/10.1007/BF02968620
Issue Date:
DOI: https://doi.org/10.1007/BF02968620